Turn cryo-EM bottlenecks into competitive advantages
AAV capsid–antibody epitope maps typically delivered in 3 weeks. Specialist cryo-EM data analysis for gene therapy, vaccine, and nanoparticle teams — built on methods developed at the University of Oxford and published in leading structural biology journals.
What we do
We specialise in the cryo-EM and cryo-ET analysis of viral capsids, enveloped viruses, VLPs, and lipid- and membrane-based nanoparticles. Cryo-electron tomography and subtomogram averaging have been our core technique since 2008 — the methods that work when particles are flexible, pleiomorphic, or heterogeneous and standard single-particle pipelines hit their limits.
AAV capsid analysis
Epitope mapping and capsid engineering support for gene therapy
High-resolution structures of AAV capsids and AAV–Fab complexes, using localized reconstruction to resolve bound antibodies and engineered surface features. For pre-clinical immunogenicity assessment, rational capsid redesign, and IP-defensible structural evidence. Typically 3 weeks for 3–6 complexes.
Viral antigens & VLPs
Structural characterisation for vaccine development
Single-particle analysis of icosahedral antigens and VLPs, plus cryo-ET and subtomogram averaging of enveloped viruses and their glycoprotein spikes. For immunogen design, antibody epitope mapping on pleiomorphic particles, and batch comparability where symmetry-breaking or flexibility rules out conventional pipelines.
Nanoparticle characterisation
LNPs, extracellular vesicles, liposomes, and engineered soft matter
Three-dimensional quantification of pleiomorphic nanoparticles in their native hydrated state using cryo-ET and subtomogram averaging. For mRNA and siRNA delivery programs, EV therapeutics, and engineered particles where DLS and negative-stain EM don’t answer the question — including size distribution, payload localization, and structural heterogeneity across batches.
Nanometria 